Read by QxMD icon Read

Journal of Crohn's & Colitis

Merel E Stellingwerf, Marlou A de Koning, Thomas Pinkney, Willem A Bemelman, Geert R D'Haens, Christianne J Buskens
Background: Appendectomy decreases the risk of developing ulcerative colitis (UC), and is suggested to have a beneficial effect on the clinical course of established UC. However, recent studies showed no significantly decreased colectomy rate, and moreover an apparently increased risk of colorectal cancer (CRC). We aimed to investigate the suggested correlation in a meta-analysis, and analyze possible confounding factors. Methods: A systematic review and meta-analysis were performed using MEDLINE, EMBASE and the Cochrane library...
October 18, 2018: Journal of Crohn's & Colitis
Christian Maaser
No abstract text is available yet for this article.
October 17, 2018: Journal of Crohn's & Colitis
Pauline Rivière, Andreas Münch, Pierre Michetti, Nilesh Chande, Gert de Hertogh, Patrick Schoeters, Marc Ferrante, Séverine Vermeire, Gert Van Assche
Background: Evidence for second line therapy in patients with microscopic colitis (MC) failing budesonide is scarce, although anti-tumor necrosing factors (anti-TNFs), methotrexate and azathioprine have been reported to be effective in small cohort studies. Vedolizumab, a monoclonal antibody targeting α4β7-integrin, prevents homing of T-cells to the gut. We evaluated clinical remission with vedolizumab in budesonide-refractory MC patients. Methods: We solicited gastroenterologists in Europe and Canada for cases of MC treated with vedolizumab...
October 17, 2018: Journal of Crohn's & Colitis
Fernando Magro, Cláudia Camila Dias, Francisco Portela, Mário Miranda, Samuel Fernandes, Sonia Bernardo, Paula Ministro, Paula Lago, Isadora Rosa, Inês Pita, Luis Correia, Pedro Pereira Rodrigues
Introduction: Ulcerative colitis (UC) is a chronic inflammatory disease often accompanied by severe and distressing symptoms that, in some patients, might require a surgical intervention (colectomy). This study aimed at determining the risk of experiencing progressive disease or requiring colectomy. Material and Methods: This was a multicenter study: patients' data (n=1481) was retrieved from the Portuguese database of inflammatory bowel disease patients. Bayesian networks and logistic regression were used to build risk matrices concerning the outcomes of interest...
October 17, 2018: Journal of Crohn's & Colitis
V Lorén, A Garcia-Jaraquemada, J E Naves, X Carmona, M Mañosa, A M Aransay, J L Lavin, I Sánchez, E Cabré, J Manyé, E Domènech
Background and aims: Steroid-refractoriness is a common and unpredictable phenomenon in ulcerative colitis (UC), but there are no conclusive studies on the molecular functions involved. We aimed to assess in depth the mechanism of action related to steroid failure by integrating transcriptomic data from UC patients, and updated molecular data on UC and glucocorticoids. Methods: miRNA and mRNA expression were evaluated by sequencing and microarrays, respectively, from rectal biopsies of patients with moderately-to-severe active UC, obtained before and on the 3rd day of steroid treatment...
October 17, 2018: Journal of Crohn's & Colitis
Julie Aarestrup, Tine Jess, Camilla Jannie Kobylecki, Børge G Nordestgaard, Kristine H Allin
Background and Aims: Patients with inflammatory bowel disease have increased risks of cardiovascular diseases but the role of traditional and non-traditional cardiovascular risk factors remains unclear. We investigated if the cardiovascular risk profile differs between patients with inflammatory bowel disease and individuals in the general population. Methods: We included a population of 108,789 participants from The Copenhagen General Population Study of individuals of Danish descent aged 20-100 years...
October 13, 2018: Journal of Crohn's & Colitis
Robyn Laura Kosinsky, Robert Lorenz Chua, Martin Qui, Dominik Saul, Dawid Mehlich, Philipp Ströbel, Hans-Ulrich Schildhaus, Florian Wegwitz, William A Faubion, Steven A Johnsen
Background and Aims: Inflammatory bowel diseases are linked to an increased risk of developing colorectal cancer (CRC). Previous studies suggested that the H2B ubiquitin ligase RING finger protein-20 (RNF20) inhibited inflammatory signaling mediated by the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). However, the role of RNF40, the obligate heterodimeric partner of RNF20, in the context of inflammation and CRC has not been addressed. Here, we examined the effect of RNF40 loss on CRC cells in vitro and on inflammation and inflammatory signaling in vitro and in vivo...
October 13, 2018: Journal of Crohn's & Colitis
Geoffrey C Nguyen, Shelley Bouchard, Christina Diong
Background and Aims: The number of inflammatory bowel disease (IBD) related visits to the emergency department (ED) is increasing in North America. Our study evaluates the relationship between access to specialists and utilization of ED services. Methods: We conducted a population-based study of all IBD patients in the Ontario in 2014-2015 to measure utilization of non-emergent IBD care by specialists (NICS) and ED visits. After characterizing regional variation in access to gastroenterologists and region-wide implementation of NICS, we constructed regression models to determine whether they were predictors of individual utilization of NICS and ED services...
October 12, 2018: Journal of Crohn's & Colitis
Tim Dierckx, Bram Verstockt, Séverine Vermeire, Johan van Weyenbergh
Background and aims: Glycoprotein acetylation (GlycA) is a novel nuclear magnetic resonance (NMR) biomarker measured in serum or plasma, which summarizes signal originating from glycan groups of certain acute phase glycoproteins. This biomarker has been shown to be robustly associated to cardiovascular and short-term all-cause mortality, and to disease severity in several inflammatory conditions. We investigated GlycA levels in a cohort of healthy individuals (HC), Crohn's disease (CD) and ulcerative colitis (UC) patients prior to and after therapeutic control of inflammation...
October 11, 2018: Journal of Crohn's & Colitis
D Mege, F Colombo, M E Stellingwerf, A Germain, L Maggiori, D Foschi, C J Buskens, A de Buck van Overstraeten, G Sampietro, A D'Hoore, W Bemelman, Y Panis
Background and Aims: Although laparoscopic a1pproach is associated with the reduction of adhesions, no data are available about risk factors for small bowel obstruction (SBO) after laparoscopic ileal pouch-anal anastomosis (IPAA). The objective is to identify risk factors for SBO after laparoscopic IPAA for inflammatory bowel disease (IBD). Methods: All consecutive patients undergoing laparoscopic IPAA for IBD in 4 European expert centres were included and divided into Groups A (SBO during follow up) and B (no SBO)...
October 11, 2018: Journal of Crohn's & Colitis
Javier P Gisbert, María Chaparro
The protein domain is likely the most ubiquitously affected in disease, response and recovery, and therefore proteomics holds special promise for biomarker discovery in general, and particularly in inflammatory bowel disease (IBD), i.e., ulcerative colitis and Crohn's disease. Tremendous progress has been made over the past decade in the development and refinement of proteomic technologies. These advances provide opportunities for a long-anticipated personalized medicine approach to the treatment of IBD. The present review examines the current state of IBD proteomics research and its real usefulness in clinical practice...
October 10, 2018: Journal of Crohn's & Colitis
Shahar Bar Yehuda, Rachel Axlerod, Ori Toker, Nir Zigman, Iris Goren, Vered Mourad, Natan Lederman, Nurit Cohen, Eran Matz, Doron Dushnitzky, Matan Gavish, Nirit Borovsky, Doron Schwarts, Iris Dotan, Dan Turner
Introduction: There are conflicting data on the association between inflammatory bowel diseases (IBD) and autoimmunity disorders. The aim of this study was to explore this association including the effect of medications on this association. Methods: We utilized health administrative data collected by 3 of 4 Israel's Health Maintenance Organizations (HMO) covering 52% of the population of Israel. We explored the prevalence of the following autoimmune disorders: Insulin Dependent Diabetes Mellitus (IDDM), psoriasis, Sjögren syndrome, celiac, systemic lupus erythematosus (SLE), primary sclerosis cholangitis (PSC) and autoimmune thyroiditis, among all IBD patients versus non-IBD controls...
October 9, 2018: Journal of Crohn's & Colitis
Fabio Salvatore Macaluso, Walter Fries, Antonio Carlo Privitera, Maria Cappello, Sebastiano Siringo, Gaetano Inserra, Antonio Magnano, Roberto Di Mitri, Filippo Mocciaro, Nunzio Belluardo, Giuseppe Scarpulla, Giovanni Magrì, Antonino Trovatello, Antonio Carroccio, Salvatore Genova, Carmelo Bertolami, Roberto Vassallo, Claudio Romano, Michele Citrano, Salvatore Accomando, Marco Ventimiglia, Sara Renna, Rosalba Orlando, Giulia Rizzuto, Serena Porcari, Concetta Ferracane, Mario Cottone, Ambrogio Orlando
Background and Aims: There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicenter, real-life comparison of the effectiveness of infliximab (IFX) and adalimumab (ADA) in Crohn's disease (CD). Methods: Data of consecutive patients with CD treated with IFX and ADA from January 2013 to May 2017 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease...
October 6, 2018: Journal of Crohn's & Colitis
Owein Guillemot-Legris, Valentin Mutemberezi, Baptiste Buisseret, Adrien Paquot, Vittoria Palmieri, Pauline Bottemanne, Julien Lemaire, Jean-François Rahier, Mireille Alhouayek, Giulio G Muccioli
Background and aims: Inflammatory bowel diseases (IBD) represent a challenging health issue with a complex etiology implicating genetic and environmental parameters. Although the understanding of their pathophysiology has improved, much remains to be explored. In this context, bioactive lipids, more specifically oxysterols, i.e. oxygenated derivatives of cholesterol, represent an interesting avenue to investigate. Indeed, oxysterols or their receptors are involved in inflammation and immune regulation...
October 6, 2018: Journal of Crohn's & Colitis
Johan Burisch, Konstantinos H Katsanos, Dimitrios K Christodoulou, Luisa Barros, Fernando Magro, Natalia Pedersen, Jens Kjeldsen, Zsuzsanna Vegh, Peter L Lakatos, Carl Eriksson, Jonas Halfvarson, Mathurin Fumery, Corinne Gower-Rousseau, Marko Brinar, Silvija Cukovic-Cavka, Inna Nikulina, Elena Belousova, Sally Myers, Shaji Sebastian, Gediminas Kiudelis, Limas Kupcinskas, Doron Schwartz, Selwyn Odes, Ioannis P Kaimakliotis, Daniela Valpiani, Renata D'Incà, Riina Salupere, Stefania Chetcuti Zammit, Pierre Ellul, Dana Duricova, Martin Bortlik, Adrian Goldis, Hendrika Adriana Linda Kievit, Alina Toca, Svetlana Turcan, Jóngerð Midjord, Kári Rubek Nielsen, Karina Winther Andersen, Vibeke Andersen, Ravi Misra, Naila Arebi, Pia Oksanen, Pekka Collin, Luisa de Castro, Vicent Hernandez, Ebbe Langholz, Pia Munkholm
Background and Aims: Few population-based cohort studies have assessed the disease course of ulcerative colitis [UC] in the era of biological therapy and widespread use of immunomodulators. The aim of this study was to assess the 5-year outcome and disease course of patients with UC in the Epi-IBD cohort. Methods: In a prospective, population-based inception cohort of unselected patients with UC, patients were followed up from the time of their diagnosis, which included the collection of their clinical data, demographics, disease activity, medical therapy, and rates of surgery, cancers, and deaths...
October 5, 2018: Journal of Crohn's & Colitis
Alessandro Armuzzi, Luisa Avedano, Kay Greveson, Taegyun Kang
The increasing prevalence of inflammatory bowel disease and the high costs associated with biological therapies suggest that biologicals with lower costs, but no compromise on efficacy and safety, should be considered when developing a treatment plan for inflammatory bowel disease. Biosimilars offer a more cost-effective alternative, and although the European Medicines Agency has approved the use of biosimilars for many indications, including inflammatory bowel disease, patients may be concerned about the safety and efficacy of these agents...
October 4, 2018: Journal of Crohn's & Colitis
William J Sandborn, Jean-Frédéric Colombel, Remo Panaccione, Parambir S Dulai, Maria Rosario, Charlie Cao, Morris Barocas, Karen Lasch
Background and Aims: This GEMINI 1 post hoc analysis evaluated vedolizumab efficacy for inducing deep remission in patients with ulcerative colitis and correlation between vedolizumab trough concentrations and deep remission rates. Methods: Week 6 vedolizumab responders were re-randomised to placebo or vedolizumab every 8 or 4 weeks. Deep remission at Week 52 was measured using 4 different definitions (from most to least stringent): (1) Mayo Clinic endoscopic score=0, rectal bleeding score=0 and decrease or no change from baseline in stool frequency score; (2) endoscopic score ≤1, rectal bleeding score=0 and stool frequency score=0; (3) endoscopic score ≤1, rectal bleeding score=0, decrease or no change from baseline stool frequency score, and total score [endoscopic score + rectal bleeding score + stool frequency score] ≤1; (4) endoscopic score ≤1, rectal bleeding score=0 and stool frequency score ≤1...
October 4, 2018: Journal of Crohn's & Colitis
S Sahami, M E Wildenberg, L Koens, G Doherty, S Martin, G R A M D'Haens, G Cullen, W A Bemelman, D Winter, C J Buskens
Background and Aims: The objective of this study was to examine the modulating effect of an appendectomy on the disease course of therapy-refractory ulcerative colitis [UC] patients, and to analyse appendiceal pathological characteristics predictive of pathological response. Methods: Patients with therapy-refractory UC, and referred for proctocolectomy, were invited to undergo laparoscopic appendectomy first. The primary end points were clinical response after 3 and 12 months...
October 3, 2018: Journal of Crohn's & Colitis
Carla Felice, Alessandro Armuzzi
No abstract text is available yet for this article.
October 3, 2018: Journal of Crohn's & Colitis
Annick Moens, Karen van Hoeve, Evelien Humblet, Jean-François Rahier, Peter Bossuyt, Sophie Dewit, Denis Franchimont, Elisabeth Macken, Jochen Nijs, Annelies Posen, Beatrijs Strubbe, Anneleen Van Hootegem, Wouter Van Moerkercke, Séverine Vermeire, Marc Ferrante
Background and Aims: Vedolizumab is an IgG1 anti-α4β7 integrin antibody approved for the treatment of inflammatory bowel diseases [IBD], but without clear safety data during conception, pregnancy and nursing. Animal studies showed that mucosal vascular addressin cell adhesion molecule 1 [MAdCAM-1] is expressed by maternal vessels in the placenta and recruits α4β7-expressing cells that are considered important for maternal/fetal tolerance. Blocking this interaction by vedolizumab might affect this process...
October 3, 2018: Journal of Crohn's & Colitis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"